| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 09/20/2001 | WO2001068033A2 Il-8 receptor antagonists |
| 09/20/2001 | WO2001032029A3 Compositions comprising edible oils or fats and phytosterols and/or phytostanols substantially dissolved therein |
| 09/20/2001 | WO2001027109A3 Tert.-butyl-(7-methyl-imidazo[1,2-a]pyridine-3-yl)-amine derivatives |
| 09/20/2001 | WO2001019381A3 An antioxidant preparation based on plant extracts for the treatment of circulation and chronic degenerative problems and of hypertension |
| 09/20/2001 | WO2001016358A3 Method of screening for triacyglycerol hydrolase inhibitors |
| 09/20/2001 | WO2001014581A3 Hdac4 and hdac5 in the regulation of cardiac gene expression |
| 09/20/2001 | WO2000047583A9 Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 09/20/2001 | WO2000047553A8 ALKENYL AND ALKYNYL COMPOUNDS AS INHIBITORS OF FACTOR Xa |
| 09/20/2001 | WO2000043028A9 Method of treating chronic cardiac disease |
| 09/20/2001 | WO2000018899A3 Angiotensin converting enzyme homolog and its use |
| 09/20/2001 | WO2000009537A3 Compounds having growth hormone releasing activity |
| 09/20/2001 | US20010023292 3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4 -(2,3 -dihydroxypropoxy)pyridin-2-yl)oxy)-4-hydroxybenzamidine, for example |
| 09/20/2001 | US20010023291 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants |
| 09/20/2001 | US20010023259 Nutrients, drugs |
| 09/20/2001 | US20010023257 Hypotensive agents; anticholesterol agents |
| 09/20/2001 | US20010023256 Reducing concentration of oxygen metabolites |
| 09/20/2001 | US20010023250 Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases |
| 09/20/2001 | US20010022979 Naturally extracted and synthetic hypoglycemic or hypolipidemic compositions |
| 09/20/2001 | US20010022970 Halogenated xanthan compound |
| 09/20/2001 | CA2403679A1 Il-8 receptor antagonists |
| 09/20/2001 | CA2403442A1 Use of nateglinide alone or in combination for the treatment or prevention of diabetic complications |
| 09/20/2001 | CA2403393A1 Methods and compositions for immunoregulation |
| 09/20/2001 | CA2403241A1 Pharmaceutical compositions of glycogen phosphorylase inhibitors |
| 09/20/2001 | CA2403220A1 Methods and compositions for the regulation of vasoconstriction |
| 09/20/2001 | CA2403201A1 Family of mechanically sensitive human potassium channels activated by polyunsaturated fatty acids and use thereof |
| 09/20/2001 | CA2403188A1 Pyridazinyl phenyl hydrazones useful against congestive heart failure |
| 09/20/2001 | CA2403062A1 Il-8 receptor antagonists |
| 09/20/2001 | CA2403017A1 5-amide substituted diarylamines as mex inhibitors |
| 09/20/2001 | CA2403000A1 Embryonic stem cells and neural progenitor cells derived therefrom |
| 09/20/2001 | CA2402898A1 Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines |
| 09/20/2001 | CA2402891A1 Il-8 receptor antagonists |
| 09/20/2001 | CA2402645A1 Modulation of cardiovascular injury |
| 09/20/2001 | CA2402614A1 Insulin homolog polypeptide zins4 |
| 09/20/2001 | CA2402559A1 Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds |
| 09/20/2001 | CA2402553A1 Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans |
| 09/20/2001 | CA2402549A1 Substituted beta-carbolines |
| 09/20/2001 | CA2402427A1 Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-a]pyrimidines as antidepressant agents |
| 09/20/2001 | CA2402248A1 Polypeptides and nucleic acids encoding same |
| 09/20/2001 | CA2401267A1 Use of natural compounds having antiangiogenic activity |
| 09/20/2001 | CA2400106A1 Antibodies to human cd154 |
| 09/19/2001 | EP1134286A2 Adamts polypeptides, nucleic acids encoding them, and uses thereof |
| 09/19/2001 | EP1134215A1 2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases |
| 09/19/2001 | EP1133557A2 Growth factor modulators |
| 09/19/2001 | EP1133517A1 INTRACELLULAR TARGETED DELIVERY OF COMPOUNDS BY 70 kD HEAT SHOCK PROTEIN |
| 09/19/2001 | EP1133512A2 Benzylmaltosides as inhibitors of smooth muscle cell proliferation |
| 09/19/2001 | EP1133510A2 Acylated benzylmaltosides as inhibitors of smooth muscle cell proliferation |
| 09/19/2001 | EP1133509A1 Acetal benzylmaltosides as inhibitors of smooth muscle cell proliferation |
| 09/19/2001 | EP1133508A2 Benzylglycosylamides as inhibitors of smooth muscle cell proliferation |
| 09/19/2001 | EP1133507A2 Benzyllactobionamides as inhibitors of smooth muscle cell proliferation |
| 09/19/2001 | EP1133506A2 Benzylmaltotriosides as inhibitors of smooth muscle cell proliferation |
| 09/19/2001 | EP1133494A1 8-azabicyclo 3.2.1]oct-2-ene and -octane derivatives |
| 09/19/2001 | EP1133491A1 Novel benzofurane derivatives, preparation method, use as medicines and pharmaceutical compositions containing same |
| 09/19/2001 | EP1133488A1 Propanoic acid derivatives as integrin inhibitors |
| 09/19/2001 | EP1133487A1 Scavenger compounds |
| 09/19/2001 | EP1133486A2 Nonsteroidal antiinflammatories |
| 09/19/2001 | EP1133484A2 Heterocyclic derivatives and their use as integrin inhibitors |
| 09/19/2001 | EP1133481A1 Quinoline and quinoxaline compounds as pdgf-r and/or lck tyrosine kinase inhibitors |
| 09/19/2001 | EP1133480A1 Quinoline and quinoxaline compounds as pdgf-receptor and/or lck tyrosine kinase inhibitors |
| 09/19/2001 | EP1133479A1 Quinoline and quinoxaline compounds |
| 09/19/2001 | EP1133478A1 Novel acylguanidine derivatives, method for preparing same, application as medicines and pharmaceutical compositions containing them |
| 09/19/2001 | EP1133477A1 Substituted benzimidazoles and their use as parp inhibitors |
| 09/19/2001 | EP1133476A1 Iminoguanidine derivatives, preparation method, use as medicines |
| 09/19/2001 | EP1133475A1 Substituted benzo de]isoquinoline-1,3-diones |
| 09/19/2001 | EP1133474A1 3-substituted-4-arylquinolin-2-one derivatives as potassium channel modulators |
| 09/19/2001 | EP1133473A1 New manufacturing process |
| 09/19/2001 | EP1133471A1 Hydrazine derivatives |
| 09/19/2001 | EP1133467A1 Ion channel modulating agents |
| 09/19/2001 | EP1133311A2 INFLUENCING OF ANGIGENESIS USING CD66a |
| 09/19/2001 | EP1133310A2 Artery- and vein-specific proteins and uses therefor |
| 09/19/2001 | EP1133308A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases |
| 09/19/2001 | EP1133303A2 Acetal benzylmaltosides as inhibitors of smooth muscle cell proliferation |
| 09/19/2001 | EP1133280A1 Method of preparing stable suspensions of insoluble microparticles |
| 09/19/2001 | EP0948522A4 Therapeutic and diagnostic agents capable of modulating cellular responsiveness to cytokines |
| 09/19/2001 | EP0874849B1 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives |
| 09/19/2001 | EP0871420B1 Triacetin as a transdermal penetration enhancer |
| 09/19/2001 | EP0869952B1 5-naphthalen-1-yl-1,3-dioxane derivatives, preparation and therapeutical use thereof |
| 09/19/2001 | EP0839144B1 Piperazine derivatives as therapeutic agents |
| 09/19/2001 | EP0800516B1 FIBRINOGEN RECEPTOR ANTAGONISTS HAVING SUBSTITUTED (b)-AMINO ACID RESIDUES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME |
| 09/19/2001 | EP0692984B1 Systemic effects of nitric oxide inhalation |
| 09/19/2001 | EP0612244B1 Endothelin receptor antagonists |
| 09/19/2001 | CN1313863A Inhibitors of urokinase and blood vessel fomation |
| 09/19/2001 | CN1313862A Novel 17-halogenated 19-Nor steroids, method and intermediates for preparing same, use as medicines and pharmaceutical compositions containing same |
| 09/19/2001 | CN1313855A Inhibitors of alpha4Betal mediated cell adhesion alpha Beta |
| 09/19/2001 | CN1313846A C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cystenine proteases |
| 09/19/2001 | CN1313756A Oral liquid mucoadhesive compositions |
| 09/19/2001 | CN1313343A N-terminal modified protein compositions and methods therefor |
| 09/19/2001 | CN1313280A Benzheterocyclic derivatives |
| 09/19/2001 | CN1313115A Medicinal pill for taking care of heart health |
| 09/19/2001 | CN1313109A Bashen capsule |
| 09/19/2001 | CN1313099A Centipede-snake plaster |
| 09/19/2001 | CN1071328C Arginine angalogues having nitric oxide synthase inhibitor activity |
| 09/19/2001 | CN1071327C Denzothiazine dioxides as endothelin antagonists |
| 09/19/2001 | CN1071325C Thiol derivatives with metallopeptidase inhibitory activity |
| 09/19/2001 | CN1071318C Ortho-substd. benzoyl guanidines, their preparing process and use as medicine and diagnostic reagent, and medicine contg. same |
| 09/18/2001 | US6291672 Human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them |
| 09/18/2001 | US6291522 Cyclopentane heptan(ENE)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents |
| 09/18/2001 | US6291520 Hydroxamic acid and N-hydroxyurea derivatives and their use |
| 09/18/2001 | US6291516 Contacting the cell with a composition including at least one cyclic amp agonist. |
| 09/18/2001 | US6291503 β-phenylalanine derivatives as integrin antagonists |
| 09/18/2001 | US6291502 Use of 2-imidazolyl-substituted carbinols for the production of a medicament for the treatment or phophylaxis of diseases caused by ischemic conditions |